Scholar Rock Holding Corp Logo

Scholar Rock Holding Corp

Biopharma developing medicines for neuromuscular diseases by targeting protein growth factors.

SRRK | US

Overview

Corporate Details

ISIN(s):
US80706P1030
LEI:
Country:
United States of America
Address:
301 BINNEY STREET, 2142 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Scholar Rock Holding Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and delivery of innovative medicines for serious diseases with high unmet medical needs, particularly neuromuscular diseases. The company's scientific approach utilizes a proprietary platform to selectively target protein growth factors before they are activated. This unique method aims to treat diseases by modulating key biological pathways at their source, contrasting with traditional approaches that address proteins after activation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Scholar Rock Holding Corp filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Scholar Rock Holding Corp

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Scholar Rock Holding Corp via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Greenwich LifeSciences, Inc. Logo
Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.
United States of America
GLSI
GRI Bio, Inc. Logo
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
United States of America
GRI
Grifols S.A. Logo
Leading producer of plasma-derived medicines for patients with rare and chronic diseases.
Spain
GRF
Grindeks Logo
Develops & manufactures pharmaceuticals for cardiovascular, CNS, cancer, and diabetes globally.
Latvia
GRD1R
GT Biopharma, Inc. Logo
Develops TriKE® immunotherapies engaging NK cells to treat hematologic and solid tumor cancers.
United States of America
GTBP
Guardant Health, Inc. Logo
Develops liquid biopsies for cancer detection, monitoring, and personalized treatment guidance.
United States of America
GH
Guard Therapeutics International AB Logo
Clinical-stage biotech developing drugs to prevent acute kidney injury during open-heart surgery.
Sweden
GUARD
Develops research antibodies and distributes scientific instruments for life science researchers.
South Korea
036180
GYRE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
United States of America
GYRE
Haleon PLC Logo
A global consumer healthcare leader providing trusted, science-backed OTC brands for everyday health.
United Kingdom
HLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.